核因子КB受体活化因子配基(RANKL)在非小细胞肺癌中的表达及其与血管密度的关系

Receptor activator of NF-КB Ligand (RANKL)expression and correlation of microvessel density in non-small cell lung cancer

目的探讨核因子КB受体活化因子配基(RANKL)在非小细胞肺癌(NSCLC)的表达以及与微血管密度(MVD)的关系。方法应用免疫组织化学的方法检测50例NSCLC中RANKL和CD34的表达。结果①RANKL在非小细胞肺癌中阳性表达率为62.0%(31/50),其中肺腺癌和肺鳞癌的RANKL阳性表达率分别为73.3%(22/30),45.0%(9/20),肺腺癌的RANKL蛋白阳性表达率显著高于肺鳞癌的RANKL阳性表达率(P<0.05)。②RANKL阳性组的MVD值高于RANKL阴性组,差异有显著性(P<0.05)。结论RANKL在非小细胞肺癌组织中的表达增高,可能在促进肿瘤血管的生成方面起着重要的作用。

[Objective] To investigate the receptor activator of NF-KB Ligand （RANKL） expression and the correlation of microvessel density （MVD） in non-small cell lung cancer （NSCLC）. [Methods] The expressions of RANKL and CD34 were investigated by immunohistochemistry in 50 NSCLC specimens. [Results] The positive expression percentage of RANKL in NSCLC was 62.0% （31/50）, including 73.3% （22/30）, 45.0% （9/20） in lung adenocarcinoma and squamous cell carcinoma, respectively. The positive expression percentage of RANKL in lung adenocarcinoma was significantly higher than that in lung squamous cell carcinoma （P 〈0.05）. MVD in the case with positive RANKL expression increased obviously than that in the case with negative RANKL expression （P 〈0.05）. [ Conclusion] RANKL is highly expressed in non-small cell lung cancer and may play an important role in promoting the tumor angiogenesis.